Generic Name: Abana
What is Abana?
Osteoarthritis is a joint disease. It results from the gradual breakdown of the cartilage that covers the joints and cushions the ends of bones. Symptoms of osteoarthritis include pain, tenderness, stiffness of one or more joints, and physical disability. The hips and knees are the most commonly affected joints, but other joints such as those of the hands and spine may also be affected. Osteoarthritis is more common in women than in men. Many factors can lead to the development of osteoarthritis including obesity and joint injury eg.
Rheumatoid arthritis is a chronic disease that causes pain, stiffness, swelling and loss of function in the joints and inflammation in other body organs.
COX-1, among other functions, is involved with protecting the stomach, while COX-2 plays a role in joint inflammation and pain. However taking aspirin with Arcoxia may reverse this benefit see Before you take Arcoxia, Taking Other Medicines. In clinical studies, the risk of developing ulcers on Arcoxia was lower than with NSAIDs.
Setting: 43 outpatient study centres in 11 countries. Methods Study population Eligible patients were aged 18 years or over with acute gout onset within 48 hours associated with moderate, severe, or extreme pain and meeting the American Rheumatology Association diagnostic criteria for acute gout see box on bmj.
Study design This was a randomised, double blind the investigators and sponsor were blinded throughout the studyactive comparator controlled study. Assessment of efficacy Efficacy end points included patients' assessment of pain in the study joint primary end point and investigators' assessments of tenderness, swelling, and erythema. Assessment of safety and tolerability Investigators performed physical examinations, assessed vital signs, and took samples for laboratory tests complete blood count, blood chemistry, and urinalysis at baseline and at the post-study visit.
Statistical analysis We hypothesised that etoricoxib would show clinical efficacy comparable to indometacin as evaluated by patients' assessment of pain in the study joint mean change from baseline over days 2 to 5 primary end point and over days 2 to 8 secondary end point.
Results Characteristics of the patients Forty three study centres hospital clinics, urgent care centres, and office practices in 11 countries participated. Efficacy Etoricoxib and indometacin showed comparable efficacy in the treatment of acute gouty arthritis as assessed by all efficacy end points over the first four days days 2 to 5 and over the entire treatment period days 2 to 8 fig 1. Primary end point The mean SE baseline values for patients' assessment of pain in the study joint primary end point were 2.
The four hour time point indicates the assessment four hours after the initial dose of study drug on day 1, the day of the randomisation R visit baseline Secondary end points Etoricoxib showed efficacy similar to indometacin for all secondary efficacy end points global assessments of response to treatment, joint tenderness and swelling table 1and discontinuation owing to lack of efficacy and erythema.
Safety Four serious adverse experiences were reported, all in the indometacin group: vomiting and headache determined by the investigator to be drug relateda drug overdose, and a laryngeal neoplasm determined not to be drug related. Values are numbers percentages of patients unless stated otherwiseView this table:View popupView inline Discussion Previous work has shown that cyclo-oxygenase-2 selective inhibitors provide efficacy similar to that of non-selective non-steroidal anti-inflammatory drugs in chronic inflammatory conditions and acute pain.
Acknowledgments We thank Elliot Ehrich for invaluable contributions to the design of the study, Peter Merkel for helpful suggestions regarding the study design, and Ken Truitt for guidance during the course of the study. Footnotes Funding Merck Research Laboratories, Rahway, NJ, USA, provided funding to all participating investigators to cover the costs of patient procedures and evaluations.
How should I take Abana?
Four serious adverse experiences were reported, all in the indometacin group: vomiting and headache determined by the investigator to be drug relateda drug overdose, and a laryngeal neoplasm determined not to be drug related. For all four prespecified categories of adverse experiences, etoricoxib was associated with a lower incidence than indometacin table 2. Five patients in the etoricoxib group and six in the indometacin group had one or more laboratory finding that was considered to be an adverse experience.
Analysis of prespecified adverse experiences. Values are numbers percentages of patients unless stated otherwisePrevious work has shown that cyclo-oxygenase-2 selective inhibitors provide efficacy similar to that of non-selective non-steroidal anti-inflammatory drugs in chronic inflammatory conditions and acute pain. However, the precise roles of cyclo-oxygenase-1 and cyclo-oxygenase-2 in acute inflammatory conditions such as acute gout have not been studied.
What should I avoid while taking Abana?
Open Peer Review reportsThe aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis OA patients.
Safety and tolerability were assessed by collecting adverse events throughout the study. During the 46-week active-comparator controlled period, the etoricoxib groups demonstrated clinical efficacy that was similar to that of diclofenac 150 mg and was generally well tolerated, with a lower incidence of gastrointestinal GI nuisance symptoms compared with diclofenac 13.
In this extension study, etoricoxib, at doses ranging from 30 to 90 mg, demonstrated a maintenance of significant clinical efficacy in patients with OA through 52 weeks of treatment. Etoricoxib displayed clinical efficacy similar to diclofenac 150 mg and was generally well tolerated.
Osteoarthritis OA is a disorder that involves softening and disintegration of articular cartilage, vascular congestion and increased osteoblastic activity in the subarticular bone, new bone or cartilage growth at the joint margins, and capsular fibrosis.
Abana side effects
Cochrane Database Syst Rev. Merck will continue to market Arcoxia outside the United States. Your doctor will prescribe Arcoxia for you only after you have used other medicines for your condition and they have not been suitable for you. Your doctor will want discuss your treatment with Arcoxia from time to time.
It is important that you use the lowest dose that controls your pain and you should not take Arcoxia for longer than necessary. This is because the risk of heart attacks and strokes might increase after prolonged treatment, especially with high doses.
Osteoarthritis is a joint disease. It results from the gradual breakdown of the cartilage that covers the joints and cushions the ends of bones.
Common Abana ide effects may include:
Patients who have any questions or concerns should speak to their doctor or pharmacist.
This means that it stops the production of inflammatory prostaglandins, without stopping the production of prostaglandins that protect the stomach and intestines.
UK Search Home Drug Safety Update Etoricoxib Arcoxia : revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis From: Medicines and Healthcare products Regulatory Agency Published: 17 October 2016 Therapeutic area: Pain management and palliation and Rheumatology Contents Background Trial results Further information Advice for healthcare professionals: the cardiovascular and other important risks of etoricoxib Arcoxia may increase with dose and duration of exposure.
Limit alcohol intake with this drug as it may enhance side effects, such as dizziness and drowsiness.
Always complete the full course as prescribed by your doctor. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects.
Many people using this medication do not have serious side effects.
Where can I get more information?
The discovery of COX-2, the evolution of drug development in this field and the implications.
Of these 617 patients, 550 patients entered part II the beginning of the active-comparator controlled period and 427 patients completed Part II and entered the first extension.